Market Update (NYSE:MRK): Merck Acquires IOmet Pharma and Expands Immuno-Oncology Development Program

[Business Wire] – Merck , known as MSD outside the United States and Canada, announced today that it has acquired IOmet, a privately-held UK-based drug discovery company focused on the development of innovative medicines for the treatment of cancer, with a particular emphasis on the fields of cancer immunotherapy and cancer metabolism. Read more on this. Merck & Co. Inc. (MRK) , valued at $143.17B, began trading this morning at $51.25. Today’s price range has been between $50.61 and $51.54 per share with its 52-week range being $45.69 to $63.62. MRK shares are currently priced at 14.31x this year’s forecasted earnings, which makes them relatively expensive compared to the industry’s -3.59x earnings multiple for the same period. And for passive income investors, the company pays shareholders $1.84 per share annually in dividends, yielding 3.48%. In a review of the consensus earnings estimate this quarter, 17 sell-side analysts are looking at $0.91 per share, which would be $0.04 better than the year-ago quarter and a $0.02 sequential increase. In looking at the bigger picture, the full-year EPS estimate of $3.57 would be a $0.08 improvement when compared to the previous year’s annual results. The quarterly earnings estimate is based on a consensus revenue forecast of the current quarter of $10.32 Billion. If realized, that would be a 1.53% decrease over the year-ago quarter. Recently, Berenberg Initiated MRK at Hold (Nov 24, 2015). Previously, Piper Jaffray Initiated MRK at to Neutral. The average price target for MRK shares by the analysts covering the stock is $62.26, which is 21.48% above where the stock opened this morning. See more in (NYSE:MRK) Similar Articles: Market Update (NYSE:MRK): Dynavax Initiates Immuno-Oncology Clinical Trial Evaluating SD-101 in Combination With Merck’s Anti-PD-1 Therapy, KEYTRUDA(R) (pembrolizumab) Market Update: Merck & Co Inc (NYSE:MRK) – U.S. FDA expands approval of Merck’s Keytruda to lung cancer Stock Update (NYSE:MRK): Data in Nine Difficult-to-Treat Cancers from Merck’s KEYTRUDA® (pembrolizumab) Development Program to be Presented at European Cancer Congress 2015, Including Data in Four New Cancer Types: …
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.